Article
Multidisciplinary Sciences
Weijie Cao, Xiaoning Li, Ran Zhang, Zhilei Bian, Suping Zhang, Li Li, Haizhou Xing, Changfeng Liu, Xinsheng Xie, Zhongxing Jiang, Xiaosheng Fang, Dingming Wan, Jifeng Yu
Summary: In this study, we aimed to validate and prove the effectiveness of AML-DRG and AML-HCT-CR models in predicting post-transplant survival in patients with acute myeloid leukemia (AML) receiving allogeneic hematopoietic stem cell transplantation (AHCT). Our results showed that these models significantly predicted the cumulative incidence of relapse and AML-DRG model demonstrated better stratification of AML patients into different risk groups compared to the AML-HCT-CR model. Multivariate analysis confirmed the independent prognostic impact of these models on post-transplant overall survival.
SCIENTIFIC REPORTS
(2022)
Article
Biophysics
Yosuke Okada, Hideki Nakasone, Yuhei Nakamura, Masakatsu Kawamura, Shunto Kawamura, Junko Takeshita, Nozomu Yoshino, Yukiko Misaki, Kazuki Yoshimura, Shimpei Matsumi, Ayumi Gomyo, Toshikuni Kawamura, Yu Akahoshi, Machiko Kusuda, Kazuaki Kameda, Aki Tanihara, Masaharu Tamaki, Shun-ichi Kimura, Shinichi Kobayashi, Shinichi Kako, Fumihiko Kimura, Yoshinobu Kanda
Summary: Chromosome analysis is a valuable tool for predicting prognosis in myeloid malignancies. This study retrospectively analyzed 72 recipients who experienced relapse after allogeneic hematopoietic cell transplantation (allo-HCT) and found that clonal chromosomal changes at relapse after allo-HCT were associated with shorter post-relapse survival. Acquisition of chromosome 7 abnormality or complex changes was also linked to inferior survival. Further research is needed to understand the impact of individual chromosomal changes.
BONE MARROW TRANSPLANTATION
(2022)
Article
Immunology
Zeynep Arzu Yegin, Zubeyde Nur Ozkurt, Asena Dikyar, Lale Aydin Kaynar, Ozlem Karacaoglu, Munci Yagci
Summary: The study examined the predictive role of pretransplant HCT-composite risk (HCT-CR) score in alloHCT recipients, finding that lower HCT-CR scores were associated with significantly better overall survival and leukemia-free survival outcomes compared to higher risk categories.
TRANSPLANTATION PROCEEDINGS
(2021)
Article
Oncology
Yiwen Ling, Na Xu, Ke Zhao, Lijie Han, Qing Zhang, Zhiping Fan, Fen Huang, Zhuowen Chen, Li Xuan, Hui Liu, Jun Xu, Xiaoxia Chen, Sijian Yu, Hongsheng Zhou, Jing Sun, Qifa Liu
Summary: Emerging evidence suggests that CDKN2 deletion may be a poor prognostic predictor in adult B-ALL. Adult B-ALL patients with CDKN2 deletion may benefit from allogeneic hematopoietic cell transplant.
Article
Oncology
Bhagirathbhai Dholaria, Myriam Labopin, Jaime Sanz, Annalisa Ruggeri, Jan Cornelissen, Helene Labussiere-Wallet, Didier Blaise, Edouard Forcade, Patrice Chevallier, Anna Grassi, Ludmila Zubarovskaya, Jurgen Kuball, Patrice Ceballos, Fabio Ciceri, Frederic Baron, Bipin N. Savani, Arnon Nagler, Mohamad Mohty
Summary: This study compared the outcomes of CBT and single-allele-mismatched MMUD allo-HCT with PTCy in acute myeloid leukemia. The results showed that CBT was associated with higher incidence of graft failure and non-relapse mortality compared to MMUD, leading to lower leukemia-free survival, overall survival, and GVHD-free, relapse-free survival. In conclusion, MMUD allo-HCT with PTCy may be a preferred choice over CBT for patients without a fully matched donor.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Oncology
Li Xuan, Qifa Liu
Summary: Relapse is still the main reason for treatment failure in AML patients undergoing allo-HSCT. Evidence suggests that maintenance therapy post-transplantation, particularly targeted drugs like hypomethylating agents, FLT3 inhibitors, and isocitrate dehydrogenase inhibitors, could benefit AML patients, especially those at high risk.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Hematology
Caner Saygin, Gregory Roloff, Christopher N. Hahn, Rakchha Chhetri, Saar Gill, Hany Elmariah, Chetasi Talati, Emma Nunley, Guimin Gao, Aelin Kim, Michael Bishop, Satyajit Kosuri, Soma Das, Deepak Singhal, Parvathy Venugopal, Claire C. Homan, Anna Brown, Hamish S. Scott, Devendra Hiwase, Lucy A. Godley
Summary: There is growing recognition that pathogenic germ line variants play a role in the development of hematopoietic cancers. Patients with myeloid malignancies and deleterious germ line DDX41 variants have a higher incidence of severe acute GVHD. The use of posttransplant cyclophosphamide can reduce the risk of severe acute GVHD in these patients.
Article
Hematology
Sanam Shahid, Nicholas Ceglia, Jean-Benoit Le Luduec, Andrew Mcpherson, Barbara Spitzer, Theodota Kontopoulos, Viktoria Bojilova, M. Kazim Panjwani, Mikhail Roshal, Sohrab P. Shah, Omar Abdel-Wahab, Benjamin Greenbaum, Katharine C. Hsu
Summary: This study investigated the effects of allo-HCT on AML cells using a novel single-cell proteogenomic approach. The results demonstrated immune-related transcriptional signatures in posttransplant relapses, revealing dysfunction in activated natural killer cells and CD8+ T-cell subsets, as well as an expansion of dysfunctional T cells.
Article
Multidisciplinary Sciences
Youjin Wang, Weiyin Zhou, Lisa J. McReynolds, Hormuzd A. Katki, Elizabeth A. Griffiths, Swapna Thota, Mitchell J. Machiela, Meredith Yeager, Philip McCarthy, Marcelo Pasquini, Junke Wang, Ezgi Karaesmen, Abbas Rizvi, Leah Preus, Hancong Tang, Yiwen Wang, Loreall Pooler, Xin Sheng, Christopher A. Haiman, David Van Den Berg, Stephen R. Spellman, Tao Wang, Michelle Kuxhausen, Stephen J. Chanock, Stephanie J. Lee, Theresa E. Hahn, Lara E. Sucheston-Campbell, Shahinaz M. Gadalla
Summary: Chromosomal aberrations in pre-HCT peripheral blood of AML patients were analyzed to identify predictors of survival post-transplant. CNLOH in chr17p for CR patients and chr13q for non-CR patients were associated with poor outcomes, with three-fold increased mortality risk even after adjusting for clinical factors. Pre-transplant CNLOH in chr13q or chr17p could be used as a predictor of poor outcomes in AML patients undergoing unrelated donor HCT, warranting further large prospective studies for validation and potential treatment strategies.
SCIENTIFIC REPORTS
(2021)
Article
Hematology
Masatomo Kuno, Satoshi Yamasaki, Nobuharu Fujii, Yasushi Ishida, Takahiro Fukuda, Keisuke Kataoka, Naoyuki Uchida, Yuta Katayama, Maho Sato, Daishi Onai, Toshihiro Miyamoto, Shuichi Ota, Satoshi Yoshioka, Takahide Ara, Akira Hangaishi, Yoshiko Hashii, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta, Yoshihiro Inamoto
Summary: The study compared myeloid neoplasms (MNs) following allogeneic hematopoietic cell transplantation (HCT) versus autologous HCT using a Japanese HCT registry database. The cumulative incidence of MNs was lower after allogeneic HCT than after autologous HCT, and those following allogeneic HCT developed in younger patients and sooner after HCT. Further research is needed to understand the mechanisms of MN development following allogeneic HCT.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Oncology
Dao-Xing Deng, Juan-Juan Wen, Yi-Fei Cheng, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Yu-Hong Chen, Huan Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Ya-Zhen Qin, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Su Zhao, Xiao-Dong Mo
Summary: Sequential monitoring of WT1 after allo-HSCT can predict relapse in pediatric AML, and WT1-directed immunotherapy may have the potential to prevent relapse and improve survival.
Article
Oncology
Asmita Mishra, Roni Tamari, Amy E. DeZern, Michael T. Byrne, Mahasweta Gooptu, Yi-Bin Chen, H. Joachim Deeg, David Sallman, Phillip Gallacher, Anders Wennborg, Denice K. Hickman, Eyal C. Attar, Hugo F. Fernandez
Summary: This study evaluated the efficacy and safety of Eprenetapopt combined with azacitidine as maintenance therapy after HCT in patients with mTP53 AML and MDS. The results showed that this treatment regimen was well tolerated and achieved encouraging RFS and OS outcomes in this high-risk population.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Hematology
Kevin-James Wattebled, Elodie Drumez, Valerie Coiteux, Leonardo Magro, Micha Srour, Paul Chauvet, Bruno Quesnel, Alain Duhamel, Ibrahim Yakoub-Agha, David Beauvais
Summary: Single-agent AZA does not appear to be an optimal drug for preventing posttransplant relapse in patients with high-risk myeloid malignancies. This study highlights the need for prospective studies of alternative therapies or combination approaches in the post-transplant setting.
ANNALS OF HEMATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Mark-Alexander Schwarzbich, Hao Dai, Lambros Kordelas, Dietrich W. Beelen, Aleksandar Radujkovic, Carsten Mueller-Tidow, Peter Dreger, Thomas Luft
Summary: The study demonstrates that pre-conditioning serum Leptin levels can serve as an independent prognostic marker for relapse following alloSCT in high-risk acute leukemia patients, particularly those in the intermediate to advanced stages. This effect was validated in an independent cohort, suggesting the potential utility of serum Leptin for predicting post-transplant outcomes in certain patient populations.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Masamitsu Yanada, Shohei Mizuno, Satoshi Yamasaki, Kaito Harada, Takaaki Konuma, Hiroya Tamaki, Naoki Shingai, Naoyuki Uchida, Yukiyasu Ozawa, Masatsugu Tanaka, Makoto Onizuka, Masashi Sawa, Hirohisa Nakamae, Souichi Shiratori, Ken-ichi Matsuoka, Tetsuya Eto, Toshiro Kawakita, Yumiko Maruyama, Tatsuo Ichinohe, Yoshinobu Kanda, Yoshiko Atsuta, Jun Aoki, Shingo Yano
Summary: The study compared outcomes of allogeneic hematopoietic cell transplantation for de novo AML, AML evolving from MDS, and MDS-EB, showing significant differences in overall survival probabilities. Higher risks of non-relapse mortality and relapse were associated with AML evolving from MDS and MDS-EB, indicating the need to reduce these risks for improved outcomes.
LEUKEMIA & LYMPHOMA
(2021)
Review
Biophysics
Stefan O. Ciurea, Monzr M. Al Malki, Piyanuch Kongtim, Ephraim J. Fuchs, Leo Luznik, Xiao-Jun Huang, Fabio Ciceri, Franco Locatelli, Franco Aversa, Luca Castagna, Andrea Bacigalupo, Massimo Martelli, Didier Blaise, Patrick Ben Soussan, Yolande Arnault, Rupert Handgretinger, Denis-Claude Roy, Paul V. O'Donnell, Asad Bashey, Scott Solomon, Rizwan Romee, Jorge Gayoso, Hillard M. Lazarus, Karen Ballen, Bipin N. Savani, Mohamad Mohty, Arnon Nagler
BONE MARROW TRANSPLANTATION
(2020)
Article
Hematology
Piyanuch Kongtim, Omar Hasan, Jorge Miguel Ramos Perez, Ankur Varma, Sa A. Wang, Keyur P. Patel, Julianne Chen, Gabriela Rondon, Samer Srour, Qaiser Bashir, Muzaffar Qazilbash, Rohtesh Mehta, Elizabeth J. Shpall, Amin Alousi, Issa Khouri, Partow Kebriaei, Uday Popat, Richard R. Champlin, Stefan O. Ciurea
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
(2020)
Article
Hematology
Bhagirathbhai Dholaria, Bipin N. Savani, Myriam Labopin, Leo Luznik, Annalisa Ruggeri, Stephan Mielke, Monzr M. Al Malki, Piyanuch Kongtim, Ephraim Fuchs, Xiao-Jun Huang, Franco Locatelli, Franco Aversa, Luca Castagna, Andrea Bacigalupo, Massimo Martelli, Didier Blaise, Patrick Ben Soussan, Yolande Arnault, Rupert Handgretinger, Denis-Claude Roy, Paul O'Donnell, Asad Bashey, Scott Solomon, Rizwan Romee, Philippe Lewalle, Jorge Gayoso, Michael Maschan, Hillard M. Lazarus, Karen Ballen, Sebastian Giebel, Frederic Baron, Fabio Ciceri, Jordi Esteve, Norbert-Claude Gorin, Alexandros Spyridonidis, Christoph Schmid, Stefan O. Ciurea, Arnon Nagler, Mohamad Mohty
Article
Hematology
Stefan O. Ciurea, Piyanuch Kongtim, Ankur Varma, Gabriela Rondon, Julianne Chen, Samer Srour, Qaiser Bashir, Amin Alousi, Rohtesh Mehta, Betul Oran, Uday Popat, Chitra Hosing, Amanda Olson, Naval Daver, Marina Konopleva, Richard E. Champlin
Article
Oncology
Stefan O. Ciurea, Piyanuch Kongtim, Omar Hasan, Jorge M. Ramos Perez, Janet Torres, Gabriela Rondon, Richard E. Champlin
CLINICAL CANCER RESEARCH
(2020)
Article
Oncology
Cai Xu, Jian-Yue Jin, Ming Zhang, Amy Liu, Jun Wang, Radhe Mohan, Fengming (Spring) Kong, Steven H. Lin
RADIOTHERAPY AND ONCOLOGY
(2020)
Meeting Abstract
Oncology
Nirav Antao, Abhishek R. Chilkulwar, Suhong Luo, Kenneth Robert Carson, Kristen Marie Sanfilippo, Martin W. Schoen
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Hematology
Stefan O. Ciurea, Monzr M. Al Malki, Piyanuch Kongtim, Jun Zou, Fleur M. Aung, Gabriela Rondon, Julianne Chen, Michiko Taniguchi, Salman Otoukesh, Auayporn Nademanee, Stephen J. Forman, Richard Champlin, Ketevan Gendzekhadze, Kai Cao
Summary: DSAs are a major cause of engraftment failure in HaploSCT patients. Treatment with PE, rituximab, IVIg, and donor buffy coat is effective in promoting engraftment in patients with DSAs 20,000 MFI or below.
Review
Hematology
Pongthep Vittayawacharin, Piyanuch Kongtim, Stefan O. Ciurea
Summary: Myelodysplastic syndromes (MDS) are a group of diverse hematopoietic stem cell tumors primarily affecting older individuals, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment. In recent years, the use of reduce-intensity conditioning regimens and haploidentical donors for transplantation has improved treatment outcomes. However, treatment-related mortality remains a limitation, highlighting the importance of pre-transplant evaluation for older patients.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Letter
Hematology
Benjamin J. Lee, Shawn P. Griffin, Jean Doh, Alexandre Chan, Susan O'Brien, Deepa Jeyakumar, Stefan O. Ciurea, Pamela S. Becker, Piyanuch Kongtim
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Letter
Hematology
Benjamin J. J. Lee, Shawn P. P. Griffin, Jean Doh, Piyanuch Kongtim, Alexandre Chan, Susan O'Brien, Deepa Jeyakumar, Stefan O. O. Ciurea
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Sung-Eun Lee, Feng Wang, Maison Grefe, Abel Trujillo-Ocampo, Wilfredo Ruiz-Vasquez, Koichi Takahashi, Hussein A. Abbas, Pamella Borges, Dinler Amaral Antunes, Gheath Al-Atrash, Naval Daver, Jeffrey J. Molldrem, Andrew Futreal, Guillermo Garcia-Manero, Jin S. Im
Summary: The purpose of this study is to find immune-related biomarkers to predict effective antitumor immunity in myelodysplastic syndrome (MDS) during immunotherapy and/or hypomethylating agent treatment. Peripheral blood samples from 55 MDS patients were analyzed for immune subsets, T-cell receptor repertoire, gene mutations, and immune-related gene expression profiling. The results showed that clinical responders to immunotherapy exhibited expansion of central memory CD8+ T cells, diverse TCR repertoire, higher mutation burden, and favorable changes in immune landscape.
CLINICAL CANCER RESEARCH
(2023)
Article
Hematology
Benjamin J. Lee, Piyanuch Kongtim, Jean Doh, Shawn P. Griffin, Alexandre Chan, Susan O'Brien, Stefan O. Ciurea, Deepa Jeyakumar
Summary: The use of triple intrathecal (IT) chemotherapy during HyperCVAD is a feasible alternative to standard of care (SOC) CNS prophylaxis for the treatment of acute lymphoblastic leukemia (ALL). It does not result in differences in CNS relapse-free survival, cumulative incidence of relapse, or overall survival compared to SOC. However, it significantly reduces the number of IT doses administered and the need for additional outpatient appointments.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Uday R. Popat, Oren Pasvolsky, Roland Bassett Jr, Rohtesh S. Mehta, Amanda Olson, Julianne Chen, Amin M. Alousi, Gheath Al-Atrash, Qaiser Bashir, Alison M. Gulbis, Chitra M. Hosing, Jin S. Im, Partow Kebriaei, Issa Khouri, David Marin, Yago Nieto, Betul Oran, Neeraj Saini, Terri Lynn Shigle, Samer A. Srour, Jeremy L. Ramdial, Katayoun Rezvani, Muzaffar H. Qazilbash, Borje S. Andersson, Richard E. Champlin, Elizabeth J. Shpall
Summary: A fractionated myeloablative busulfan regimen was found to be effective in reducing nonrelapse mortality without increasing relapse rate for patients undergoing allogeneic hematopoietic cell transplantation, especially for older patients and those with comorbidities.
Article
Engineering, Biomedical
Cong Zhu, Steven H. Lin, Xiaoqian Jiang, Yang Xiang, Zayne Belal, Goo Jun, Radhe Mohan
PHYSICS IN MEDICINE AND BIOLOGY
(2020)